Wan Zhiyong, Cui Meng, Yang Jia, Liao Dan, Chen Junliang, Li Fanmin, Xiang Yin, Cui Zhiwei, Yang Yang
Department of General Practice, People's Hospital of Leshan, Leshan, China.
Department of Medical Laboratory, People's Hospital of Leshan, Leshan, China.
Front Oncol. 2025 Jan 14;14:1531219. doi: 10.3389/fonc.2024.1531219. eCollection 2024.
Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.
PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.
A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, = 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, =0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.
High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.
CD8 + T细胞上PD-1表达增加被认为是T细胞耗竭的标志，并且被认为与癌症患者的预后相关。然而，结果不一致使得难以将PD-1 + CD8 + T细胞与肿瘤预后应用于临床实践。因此，我们进行了一项荟萃分析以评估其在人类癌症中的预后价值。
严格遵循PRISMA报告指南进行当前的荟萃分析。从创刊到2024年11月检索PubMed、科学网、Embase数据库。汇总各文章中PD-1 + CD8 + T细胞与总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）关联的合并风险比（HR）及其95%置信区间（CI）。对地区、标本类型、癌症类型、治疗、检测方法和癌症分期进行亚组分析。
我们的研究共纳入20项研究（23个队列，3086例癌症患者）。癌症患者中PD-1 + CD8 + T细胞的表达倾向于预测较差的总生存期（OS）（HR：1.379，95%CI：1.084 - 1.753，P = 0.009）和不利的无病生存期（DFS）（HR：1.468，95%CI：0.931 - 2.316，P = 0.099），尽管未达到统计学意义。Begg检验和Egger检验表明不存在明显的发表偏倚。
CD8 + T细胞上高PD-1表达与较差的生存结果相关，这可能潜在地用作恶性肿瘤的预后标志物。
